Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 14Unknown 10Recruiting 9Active not recruiting 8Terminated 7Withdrawn 1Not yet recruiting 1No longer available 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 250Lung Neoplasms 176Small Cell Lung Carcinoma 37Breast Neoplasms 37Neoplasms 25Neoplasm Metastasis 19Adenocarcinoma of Lung 17Ovarian Neoplasms 14Mesothelioma, Malignant 14Melanoma 13Stomach Neoplasms 12Mesothelioma 12Brain Neoplasms 12Squamous Cell Carcinoma of Head and Neck 11Colorectal Neoplasms 11Prostatic Neoplasms 10Esophageal Neoplasms 10Pancreatic Neoplasms 9Carcinoma, Renal Cell 9Lung Diseases 7Head and Neck Neoplasms 7Colonic Neoplasms 7Uterine Cervical Neoplasms 6Urinary Bladder Neoplasms 6Triple Negative Breast Neoplasms 5Thymoma 5Sarcoma 5Pleural Effusion, Malignant 5Carcinoma, Ovarian Epithelial 5Carcinoma 5

Interventions

necitumumab 1Gemcitabine 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Respiratory Tract Diseases × Thoracic × Clear all
NCT02941601 2019-09-27

A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Naïve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)

Eli Lilly and Company

Phase 2 Withdrawn
Thoracic

Lung Diseases, Lung Neoplasms, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡